You can buy or sell Curis and other stocks, options, and ETFs commission-free!
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. Read More The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA. The listed name for CRIS is Curis, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 3, After Hours